<DOC>
	<DOCNO>NCT00053053</DOCNO>
	<brief_summary>RATIONALE : Nutritional supplement may help prevent loss appetite , weight loss , fatigue patient advance cancer . PURPOSE : Randomized phase III trial compare effectiveness two nutritional supplement prevent loss appetite , weight loss , fatigue patient stage III stage IV solid tumor .</brief_summary>
	<brief_title>Comparison Nutritional Supplements Preventing Weight Loss Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare change lean body mass patient treat Juven® v non-Juven® supplement . - Compare change fatigue quality life patient treat supplement . - Compare result plethysmography , bioimpedance , skinfold measurement patient treat supplement . - Compare weight change patient treat supplement . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord primary disease site ( lung v others ) , concurrent chemotherapy ( yes v ) , evidence metastasis ( yes v ) , degree weight loss ( 2-5 % vs 6-10 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral Juven® supplement twice daily 8 week . - Arm II : Patients receive oral non-Juven® supplement twice daily 8 week . All patient undergo lean body mass measurement ( include multiple body composition weight change ) fatigue quality life assessment baseline 4 8 week . PROJECTED ACCRUAL : A total 468 patient ( 234 per treatment arm ) accrue study within 16 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor lymphoma leukemic aspect Stage III IV stage associate current metastatic disease presentation No primary metastatic brain tumor Weight loss least 2 % 10 % within past 3 month No ascites PATIENT CHARACTERISTICS : Age 17 Performance status Zubrod 02 Life expectancy At least 3 month Hematopoietic Not specify Hepatic Not specify Renal No hypercalcemia Cardiovascular No persistent moderate severe peripheral edema No uncontrolled congestive heart failure Gastrointestinal No enteric fistula No concurrent intestinal obstruction Prior intestinal obstruction allow Other Not pregnant nursing Negative pregnancy test No uncontrolled infection No serious medical illness No metabolic disorder PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Concurrent chemotherapy allow Endocrine therapy No dexamethasone appetite stimulant Intermittent dexamethasone concurrent chemotherapy allow Radiotherapy Concurrent radiotherapy allow Surgery At least 1 week since prior minor surgery At least 3 week since prior major surgery Other At least 30 day since prior total parenteral nutrition No concurrent parenteral feeding No concurrent know appetite stimulant ( e.g. , megestrol dronabinol ) No concurrent omega 3 fatty acid congener ( e.g. , ProSure™ ) No concurrent amino acid supplement Concurrent use dietary supplement ( e.g. , Ensure® Boost ) allow Concurrent enteral feeding via PEG nasogastric tube allow</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>cachexia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>